Today's Research Reports on Emblem, OrganiGram Holdings, Oncolytics Biotech and Aptose Biosciences
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at http://rdinvesting.com and get exclusive access to our numerous research reports and market updates.
RDI Initiates Coverage on:
Emblem Corp.
https://rdinvesting.com/news/?ticker=EMC.V
OrganiGram Holdings Inc.
https://rdinvesting.com/news/?ticker=OGI.V
Oncolytics Biotech Inc.
https://rdinvesting.com/news/?ticker=ONC.TO
Aptose Biosciences Inc.
https://rdinvesting.com/news/?ticker=APS.TO
Emblem's stock edged 0.83% lower Thursday, to close the day at $1.20. The stock recorded a trading volume of 441,760 shares, which was above its three months average volume of 298,366 shares. In the last year, Emblem's shares have traded in a range of 1.09 - 2.76. The stock is currently trading 56.52% below its 52 week high. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $1.26 is below its 200-day moving average of $1.47.Shares of Emblem have fallen approximately 47.37 percent year-to-date.
Access RDI's Emblem Corp. Research Report at:
https://rdinvesting.com/news/?ticker=EMC.V
On Thursday, shares of OrganiGram Holdings recorded a trading volume of 176,251 shares, which was below the three months average volume of 754,957 shares. The stock ended the day 0.77% lower at 5.18. The share price has gained 145.50% from its 52 week low with a 52 week trading range of 2.11 - 5.93. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $5.02 is greater than its 200-day moving average of $4.59. Shares of OrganiGram Holdings have gained approximately 26.34 percent year-to-date.
Access RDI's OrganiGram Holdings Inc. Research Report at:
https://rdinvesting.com/news/?ticker=OGI.V
Oncolytics Biotech's stock moved 2.73% higher Thursday, to close the day at $5.64. The stock recorded a trading volume of 13,521 shares, which was below its three months average volume of 32,395 shares. In the last year, Oncolytics Biotech's shares have traded in a range of 4.57 - 10.67. The share price has gained 23.41% from its 52 week low. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $6.90 is below its 200-day moving average of $7.19. Shares of Oncolytics Biotech have fallen approximately 16.59 percent year-to-date.
Access RDI's Oncolytics Biotech Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ONC.TO
On Thursday, shares of Aptose Biosciences recorded a trading volume of 57,635 shares, which was above the three months average volume of 40,714 shares. The stock ended the day 10.56% higher at 3.98. The share price has gained 142.68% from its 52 week low with a 52 week trading range of 1.64 - 5.97. The company's shares are currently trading below their 200-day moving average. The stock's 50-day moving average of $4.42 is greater than its 200-day moving average of $4.28. Shares of Aptose Biosciences have gained approximately 43.17 percent year-to-date.
Access RDI's Aptose Biosciences Inc. Research Report at:
https://rdinvesting.com/news/?ticker=APS.TO
Our Actionable Research on Emblem Corp. (TSXV:EMC.V) and OrganiGram Holdings Inc. (TSXV:OGI.V) and Oncolytics Biotech Inc. (TSX:ONC.TO) and Aptose Biosciences Inc. (TSX:APS.TO) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com